Androgenetic Alopecia & TRT
How Testosterone and DHT Accelerate Male-Pattern Hair Loss in Susceptible Men
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Recognized androgen-dependent process
Reference only. Not medical advice.
What can go wrong
TRT can accelerate male-pattern hair loss in genetically predisposed men by increasing androgenic substrate; this is a cosmetic, not life-threatening, effect but a frequently under-counseled one. 5-AR inhibitors (finasteride, dutasteride) slow loss but carry their own sexual side-effect profile and the contested post-finasteride syndrome, and they confound PSA screening. Men should not assume hair loss on TRT means the dose is 'too high' or unsafe; it reflects genetic follicular sensitivity.
This is something to take to a clinician. The Atlas can tell you what is known about androgenetic alopecia & trt in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Male-pattern hair loss (androgenetic alopecia) is an androgen-dependent miniaturization of scalp follicles in genetically predisposed men. The active driver at the follicle is dihydrotestosterone (DHT), produced from testosterone by 5-alpha-reductase. Raising serum testosterone with TRT increases substrate and can accelerate loss in men who carry the susceptibility; it does not create baldness in men who lack it. This dossier explains the 5-AR connection and the genuine trade-off of blocking it with finasteride.
Testosterone does not cause baldness; it unmasks a genetic susceptibility through DHT.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
In susceptible follicles, DHT binds androgen receptors and progressively shortens the anagen (growth) phase, producing finer, shorter, less-pigmented hairs until the follicle effectively ceases to produce visible hair. DHT is generated locally and systemically from testosterone by 5-alpha-reductase (type II predominates in scalp and prostate). Exogenous testosterone raises circulating testosterone and DHT, increasing androgenic drive at predisposed follicles; transdermal gels may raise DHT proportionally more than injections because skin is rich in 5-AR. Susceptibility is polygenic, with the androgen-receptor (AR) gene on the X chromosome a major locus.
The finasteride trade-off
Finasteride inhibits type II 5-alpha-reductase, lowering scalp and serum DHT and slowing or partially reversing miniaturization. The trade-off: it is not free. A minority of men report sexual side effects (lower libido, erectile or ejaculatory changes), and post-finasteride syndrome describes persistent symptoms reported after discontinuation in some users, a contested but seriously discussed entity. Finasteride also roughly halves PSA, which must be accounted for in prostate-cancer screening. It is a daily, indefinite commitment; stopping reverses the cosmetic benefit within months.
Safety in detail
- DHT, not testosterone, is the proximate follicular driver
- Transdermal gels may raise DHT proportionally more than injections
- Susceptibility is genetic and polygenic (AR gene implicated)
- Finasteride slows loss but has a sexual side-effect signal
- Finasteride halves PSA and confounds prostate screening
Replacement is not the same as a cycle
Supraphysiological AAS, especially DHT-derived compounds, can accelerate hair loss far beyond what replacement-dose testosterone does, because they deliver potent androgenic signaling directly. Some users add finasteride, which does not block DHT-derivative steroids that are already 5-alpha-reduced.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Scalp/Norwood pattern assessment at baseline and follow-up
- PSA interpretation adjusted if a 5-AR inhibitor is used
What people get wrong
Often saidTestosterone causes baldness
ActuallyTestosterone is only the precursor; baldness requires inherited follicular sensitivity to DHT. Men without the genetic predisposition do not go bald on TRT.
Often saidIf you are losing hair on TRT your dose is dangerous
ActuallyHair loss reflects follicular DHT sensitivity, not toxicity. The dose may be entirely appropriate for the rest of the body.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Active androgen
- Dihydrotestosterone (DHT)
- Enzyme
- 5-alpha-reductase (type II dominant in scalp/prostate)
- Process
- Follicular miniaturization, shortened anagen
- Pattern
- Frontotemporal recession + vertex (Norwood)
- Blocker
- Finasteride (5-AR inhibitor)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Androgenetic Alopecia & TRT. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Kaufman et al., finasteride 1mg in men with AGA1998
5-year RCT showing finasteride increased scalp hair count and slowed progression versus placebo
Sawaya & Price, 5-alpha-reductase isoenzymes in alopecia1997
Demonstrated higher 5-AR and DHT in balding versus non-balding scalp, anchoring the DHT mechanism